Analyst Swayampakula Ramakanth from H.C. Wainwright maintained a Buy rating on Bicycle Therapeutics and keeping the price target at $33.00.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Swayampakula Ramakanth has given his Buy rating due to a combination of factors that highlight the potential and current valuation of Bicycle Therapeutics. The company has announced a timeline shift for a significant clinical update regarding zelenectide pevedotin in metastatic urothelial cancer, with the update now expected in the first quarter of 2026. This update will include feedback from multiple regulatory agencies, which could enhance the design of a global Phase 3 study to meet various regulatory requirements, thereby increasing the potential for successful outcomes.
Additionally, Bicycle Therapeutics is trading below its cash value, presenting a compelling risk/reward opportunity. At the end of the third quarter of 2025, the company had substantial cash reserves, and its recent financial performance exceeded consensus expectations. The analyst’s valuation model, which includes a risk-adjusted net present value analysis, supports a 12-month price target of $33, indicating significant upside potential from the current trading price.
In another report released today, Barclays also maintained a Buy rating on the stock with a $15.00 price target.
Based on the recent corporate insider activity of 51 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of BCYC in relation to earlier this year.